OrbiMed: Investment Portfolio & Startup News

OrbiMed

To add a bio or update investment portfolio, please click update information.

Investment Portfolio

Charm Therapeutics raises £60m Series B led by NEA and SR One to advance next generation cancer drug

2 Sept 2025

Charm Therapeutics raises £60m Series B led by NEA and SR One to advance next generation cancer drug

Charm Therapeutics develops next generation cancer drugs designed to overcome treatment resistance, using an AI driven discovery platform to identify compounds for aggressive blood cancers such as AML.

OrbiMed

- Life Sciences
orbimed.com
Update Information

More venture news

Salience Labs
14 Oct 2026
Salience Labs lands a £95m Series B led by Bullhound Capital to boost AI datacentre connectivity with photonic chips
Series BDeep Tech
Scarlet
12 Oct 2026
Scarlet unlocks a £40m Series B led by Headline for AI-native certification of medical software and devices
Series BHealth
Spiko
6 Oct 2026
Spiko unlocks a £70m Series B led by NEA to make money market funds accessible to all
Series BFintech

OrbiMed: Investment Portfolio & Startup News

Investment Portfolio

Charm Therapeutics raises £60m Series B led by NEA and SR One to advance next generation cancer drug

More venture news

Salience Labs lands a £95m Series B led by Bullhound Capital to boost AI datacentre connectivity with photonic chips

Scarlet unlocks a £40m Series B led by Headline for AI-native certification of medical software and devices

Spiko unlocks a £70m Series B led by NEA to make money market funds accessible to all